United States · Platforms & data · The Motley Fool

Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.

Published by The Motley Fool · United States 1 h ago

Viking aims to enter the weight loss drug market.

Read the full article on The Motley Fool Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

Trainline (LON:TRN) Given Buy Rating at Shore Capital Group

Natural Resource Partners declares $2.34 dividend

Tesla and SpaceX shares slide as Musk’s political push falls flat

Earnings call transcript: Lupin beats q2 2027 estimates, but margins soften

Treasury yields fall after Democrats win House and Senate majorities

Best Stocks Under $5